Seeking a Cure for HPV With DNA-targeted therapeutics.
HPV may be best known for its role as the cause of cervical cancer – the second leading cause of cancer deaths among women worldwide. But it also causes genital and other warts. Current treatments are primitive and ineffective. The scientists at NanoVir are developing treatments for HPV using DNA-Targeted therapies.
Learn more about the science behind our research.
Lead By Extensive Pharmaceutical and University Research Credentials
NanoVir was founded in 2003 by Drs. Chris Fisher and James Bashkin, both of whom bring extensive pharmaceutical and university research credentials to the company. Their HPV research has been consistently recognized by the scientific community through invited presentations and funding.
Research Recognized by the Scientific Funding Community
NanoVir's promising research into DNA-targeted treatments for HPV has been consistently recognized by the scientific funding community. ( To see issued patent, click here.)
2008 -2010
Phase 2 STTR Grant - $3,000,000
This grant will enable development of broad spectrum anti HPV compounds RO1 Grant - $1,830,000
This grant allows basic studies of antiviral mechanisms of actions
Phase 2 STTR Grant - $3,000,000
This grant will enable development of broad spectrum anti HPV compounds RO1 Grant - $1,830,000
This grant allows basic studies of antiviral mechanisms of actions
State-of-the-Art Facilities and Resources
The biological laboratory of NanoVir is located at the Southwest Michigan Innovation Center in Kalamazoo, Michigan, a 58,000 square foot multi-tenant facility. NanoVir occupies 1200 square feet of laboratory space with state-of-the art equipment, biological safety level 2 containment, and additional shared equipment available.
News Timeline
- 03/31/2011 Radio Interview with Chris Fisher on The Doctor’s Radio Show
- 08/10/10 - Kalamazoo-based NanoVir receives $3 million NIH grant
- 05/11/10 - NanoVir scientists awarded $1.83 million NIH grant
- 06/02/08 - NanoVir, LLC Receives $3M Preclinical Development NIAID Grant
- 11/11/07 - NanoVir Scientific Director Speaks at Beijing Conference